| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 7, 2025 5:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 7, 2025 5:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2024 | $4.00 | Buy | BTIG Research |
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel
DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me
DALLAS, May 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that its research partners, RCSI Skin Wounds and Trauma (SWaT) Research Center and RCSI Connolly Hospital, have been awarded Best Research Project at the 2025 Education Awards utilizing the DeepView System for their Diabetic Foot Ulcers (DFUs) project. The Education Awards recognize, encourage and celebrate excellence in third-level education across Ireland, including both state-funded and private institutions. The awards are par
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)
SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)
8-K - Spectral AI, Inc. (0001833498) (Filer)
10-Q - Spectral AI, Inc. (0001833498) (Filer)
8-K - Spectral AI, Inc. (0001833498) (Filer)
Q1 Overview Research & Development Revenue of $6.7 MillionImproved Capital Structure Reflected in Cash of $14.1 MillionContinued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its ongoing business activities. "During the first quarter we continued to execute against our strategic plan and are working hard towards our De Nov
DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that it will report financial results for the first quarter ended March 31, 2025 on Tuesday, May 13, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accessed online from the Events
2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2024") and full year ("FY 2024") ended December 31, 2024, and provided an update on its ongoing business activities. "Spectral AI achieved much in 2024. Our top-l
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
4 - Spectral AI, Inc. (0001833498) (Issuer)
BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel
DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me
DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Members